Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01076_DB08827_nanopub.RAfI183tHtRhR5LwfDsfPX5C8VjgkhxO5Sj_DyGAvQBCc#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01076_DB08827 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01076_DB08827 label "DDI between Atorvastatin and Lomitapide - Atorvastatin, and other weak CYP3A4 inhibitors (such as amiodarone, amlodipine, alprazolam, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginko, goldenseal, isoniazide, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton) increase lomitapide levels by 2-fold. Thus lomipatide should be dosed at a maximum of 30mg daily when used concomitantly with weak inhibitors of CYP3A4. [drugbank_resource:DB01076_DB08827]" assertion.
- drugbank_resource:DB01076_DB08827 identifier "drugbank_resource:DB01076_DB08827" assertion.
- drugbank_resource:DB01076_DB08827 title "DDI between Atorvastatin and Lomitapide - Atorvastatin, and other weak CYP3A4 inhibitors (such as amiodarone, amlodipine, alprazolam, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginko, goldenseal, isoniazide, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton) increase lomitapide levels by 2-fold. Thus lomipatide should be dosed at a maximum of 30mg daily when used concomitantly with weak inhibitors of CYP3A4." assertion.
- drugbank:DB08827 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01076_DB08827 assertion.
- drugbank:DB01076 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01076_DB08827 assertion.